OCUL

In the past six months (April 2026 - October 2026), Ocular Therapeutix, Inc. (OCUL) stock price lost 19.01% and 36.9% over the past 12 months. On October 9, 2026, the company reported inducement equity grants to fifteen newly hired non-executive employees. An officer, Todd Anderman, proposed selling 11,984 shares on October 8, 2026. The stock experienced a significant daily decline of 20.67% on September 28, 2026. On August 3, 2026, the company reported its second-quarter 2026 financial results and business highlights, including its plan to submit the AXPAXLI New Drug Application (NDA) for wet AMD in the fourth quarter of 2026. In February 2026, Ocular Therapeutix reported positive Week 52 topline data from its SOL-1 Phase 3 superiority clinical trial for AXPAXLI in wet AMD.